Table 1.
Clinical history of variants encoding L domain-2 mutations
| Participanta | Viral RNA loadb | CD4 + countc | ARTd | L-Domain 2e | CVL | PL | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PRI | NRTI | NNRTI | Resistance mutationsa | ||||||||
| CVL | PLf | PR | RT | ||||||||
| 4 | 4.74 | 5.87 | 113 | RTV, IDV | d4T, ABC | NVP | No | Yes | FYPLDSL | – | 1/12 |
| LYPLDSL | 8/8 | 8/12 | |||||||||
| 29 | 5.32 | 6.17 | 107 | – | ddI, 3TC | – | No | No | LCPLDSL | 1/20 | – |
| LYPLDSL | 8/8 | 8/8 | |||||||||
| 30 | 4.4 | 5.2 | 76 | – | ABC, AZT, 3TC | NVP | No | Yes | LYPTDSL | – | 16/16 |
| LYPLTASL | 8/10 | – | |||||||||
| 31 | 3.56 | 4.71 | 161 | – | 4dT, 3TC | – | No | Yes | QYPLASL | – | 1/9 |
| LYPLDSL | 8/10 | 12/12 | |||||||||
| 36 | 5.7 | 4.08 | 167 | SQV | 4dT, 3TC | – | No | No | MYPLTAL | 11/11 | 16/16 |
| 37 | 5.68 | 5.3 | 171 | – | 4dT | – | No | No | LYPLTFL | 2/21 | – |
| 39 | 3.72 | 4.57 | 158 | SQV | – | – | No | No | MYPLTSL | – | 16/16 |
aAs designated in Kemal et al. [26]
bLog copies/ml in plasma at time of sampling
cCells/ml at time of sampling
dART reported by participant at time of sampling: abacavir (ABC); zidovudine (AZT)’ stavudine (d4T); indinavir (IDV); nevirapine (NVP); ritonavir (RTV); didanosine (ddI); lamivudine (3TC); saquinavir (SQV)
eBold font, mutation relative to NL4-3 concensus sequence in Gag p6: LYPL(A or T)SL
fOrigin of variants, Cervical lavage (CVL); plasma (PL); numbers indicate the frequency among single genome variants